ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SBS Source Bio.

17.50
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Source Bio. LSE:SBS London Ordinary Share GB0009739649 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 17.50 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Source Bioscience Share Discussion Threads

Showing 3126 to 3149 of 3400 messages
Chat Pages: 136  135  134  133  132  131  130  129  128  127  126  125  Older
DateSubjectAuthorDiscuss
04/8/2015
06:27
16 pence guys - yippee. Its good news.
peterz
29/7/2015
14:27
One last thought for this week and I take a break before we get to read the interims



Whilst SBS have now acquired 6 companies , and it must be said they now seem to have a slick way of integrating these companies in quite a quick time-frame , which looks to be getting better each and every time they acquire the next company ...... ie practice makes perfect


Those of you PI's out there that look at charts and have hovered over the sell button as the chart keeps going upwards in its wave pattern , think on this.


Source Bioscience will soon become a tasty sized acquisition target itself for a much bigger preditor as its Mkt Cap, Turnover and profits grow.


Don't forget SBS now provide services to many of the top 10 Pharmas , and their range of NHS offerings and services also keeps growing

I do not want SBS sold before it reaches its potential

That is still several years away with probably another 3 acquisitions to come

However SBS can't stop a predator from bidding , it would not surprise me to see the first one bite in 2016

The institutions then holding over 95% of the shares will have their say




I hope they say no

buywell3
29/7/2015
14:11
3.2m buy just gone through

Time Price Volume Value Bid Ask B/S
14:52:56 15.5p 3,200,000 £496,000 15p 15.5p Buy



I believe 20p has been mentioned on this thread for 2015

Following the interims in August , a few weeks away , this looks on following the next market autumn update

buywell3
29/7/2015
10:49
The education system in Scotland produces some clever individuals

One has to give Scot , Laurie Turnbull chairman and former CEO of SBS , now a NED and major SBS shareholder , the credit in selecting the recent two latest Scottish acquisitions Inverclyde Biologicals and now Select Pharma.

I would not rule out a third one from Scotland.

Nick Ash the CEO and former FD is his protege , Turnbull still wields considerable influence in deciding SBS strategy , and was the man who brought SBS about.

buywell3
29/7/2015
10:09
A quote in 2012 about Select:-
Fraser Black, MD of BioCity Scotland says: “We are delighted to count Scotland’s Best New Life Science company amongst our growing group of tenants. The calibre of management and scientific expertise shown by the team is testament to the strength of the Scottish life sciences sector.

It is now ours: "one of Scotland's Best New Life Science company"

say no more: onwards and upwards

bigman
29/7/2015
09:49
The latest 'Outlook' looks very promising

Outlook

There is growing demand from the biopharma industry to simplify and shorten the product development to product approval process. Access to individual suppliers that can deliver a vertically integrated laboratory services solution, addressing multiple elements of the product development pipeline is key to this accelerated pathway and key to de-risking the supply chain.

The enlarged Group will be able to offer an integrated solution to customers, providing environmentally controlled storage in combination with an enhanced portfolio of both upstream and downstream laboratory analyses.

Laboratory analytical testing of product currently stored within the Source BioScience environmentally controlled stability storage suites will fall under the existing capability of Select and further enhance revenue from these activities.

In addition, the Board believes that the enlarged Group will retain the flexibility to realise its additional organic growth objectives and targeted investment opportunities following the proposed acquisition and that Source BioScience will have greater access to funding and other resources required to
pursue its strategy.







Proposed acquisition of Select Pharma Laboratories Ltd

Introduction

The Board is delighted to announce that it has conditionally agreed to acquire the entire issued share capital of Select for a total cash consideration of up to £7.3 million, of which up to £0.6 million is deferred for two years.

The total expenses of the transaction, including funding costs, are anticipated
to amount to £0.5 million. The Company has conditionally raised approximately £4.4 million in gross proceeds from existing and new investors, via the placing, in addition to securing £3.5 million of new debt to finance the initial consideration of £6.7 million and the expenses of the transaction.

Approximately £0.7 million of excess placing proceeds will be available, in combination with existing retained cash resources, to drive additional organic growth or acquisitive growth opportunities for the enlarged Group.


Information about Select


Select is a private, owner-managed, UK-based provider of stability storage and stability testing laboratory services. The business is profitable, cash generative and debt-free. Select has grown consistently in recent years to become a leading European provider of stability testing with attractive,
sustained operating margins and a robust, growing sales pipeline.

Select offers its customers access to accredited pharmaceutical testing including chemistry, physical and microbiological analyses for application in therapeutics batch release and product release to the EU market, in which it is a leading player. Select operates in a highly regulated industry from GMP accredited facilities, holding accreditations with the MHRA and FDA.

Batch release and product release involve the regulatory certification of batches of medicinal products by a Qualified Person prior to sale or supply. The testing ensures that each batch is in accordance with the relevant requirements.

Select’s testing services provide the business with embedded status
in customers’ product supply chains, providing good visibility on business volumes from existing customers.

The business serves an array of international markets and its customers include contract drug manufacturers, top European generics distributors and UK and EU importers of medicinal products.

Its specialty testing capability includes oncology and sterile medicinal products. Select is located in close proximity to Source BioScience’s existing operations in Scotland.

The Directors believe that the proposed acquisition will be earnings enhancing in the first full year of ownership. This statement does not constitute a profit forecast and should not be interpreted to mean that the earnings per share of Source BioScience for the first full year after the transaction will
increase.

A summary of the trading results and financial position for each of Select’s financial years ended 31 March 2012, 2013 and 2014 is set out below. This summary financial information has been extracted from the historical financial information contained in the circular being sent to shareholders in connection with the proposed acquisition, which has been prepared in accordance with the
requirements of the Listing Rules

Year ended 31 March 2014 £’000 Revenue 2,011 £'000 Gross profit 1,079

Year ended 31 March 2013 £’000 Revenue 1,375 £'000 Gross profit 762

Year ended 31 March 2012 £’000 Revenue 1,026 £'000 Gross profit 621

Year ended 31 March 2014 £’000 EBITDA 674 £'000 Profit before tax 578

Year ended 31 March 2013 £’000 EBITDA 546 £'000 Profit before tax 419

Year ended 31 March 2012 £’000 EBITDA 537 £'000 Profit before tax 453

Year ended 31 March 2014 £’000 Total gross assets 1,984 Net assets 1,288

Year ended 31 March 2013 £’000 Total gross assets 1,177 Net assets 764

Year ended 31 March 2012 £’000 Total gross assets 980 Net assets 598

Year ended 31 March 2014 £’000 Cash Flow from Operations 643

Year ended 31 March 2013 £’000 Cash Flow from Operations 308

Year ended 31 March 2012 £’000 Cash Flow from Operations 470


Since the last available filed accounts for the year ended 31 March 2014, Select has continued to trade in line with the previously observed performance. Select continues to benefit from increasing demand from contract generics manufacturers and therapeutic drug importers for access to accredited laboratory testing to support drug import license applications. The EU generally, and UK specifically, represents a significant target market for such customers and Select holds the required accreditations and has an established expertise and track record, for high quality testing and therapeutic compound certification.

Background to and reasons for the proposed acquisition

The Group’s ongoing strategy is to grow its laboratory services and products business organically combined with carefully selected acquisitions when the opportunities arise, building on the strong foundations now established in the business.

The Directors intend to improve the Group’s market position and share by increasing the range of services and products that it offers. Over the last two
years Source BioScience has successfully transformed the breadth of its operations, its laboratory services and its laboratory products portfolio. This has been made possible by the rapid integration of the recent acquisitions of the serology products and stability storage businesses.

The Board believes that Select represents a significant opportunity in the context of the Group’s stated growth and acquisition strategy as it meets a number of the Group’s acquisition criteria.

Furthermore, the proposed acquisition adds additional skills and services to the growth platform which has been created in the Group and strengthens the proposition to biopharma, healthcare products and regenerative medicine customers.

The Board considers Select to be an excellent fit with Source BioScience as it considerably enhances the Group’s laboratory services offering and believes that the proposed acquisition will provide a number of commercial, financial and operational benefits which are expected to create additional value for the Company’s shareholders.

Enhanced laboratory service offering

Source BioScience has an established laboratory services portfolio providing environmentally controlled storage, including stability storage and cryogenic storage, to the biopharma and healthcare products industries.

In addition to environmentally controlled storage, Source BioScience offers a portfolio of complementary laboratory analyses, utilising tissue-based and genomic technologies. This existing suite of expertise has particular application to pre-clinical and clinical trial samples, both upstream and
downstream to our storage activities, which adds value to our offering.

Select provides a further range of laboratory analyses that would complement those currently offered by Source BioScience; applying physical, chemical and microbiological analysis to therapeutic compounds and samples.

The combination of the Company’s genomic and tissue-based laboratory analytical services with
Select’s physical, chemical and microbiological analytical services will add breadth and depth to the Group’s services portfolio, enabling customers to access a single point of provision of outsourced services that meets a substantial element of their testing requirements.

This will strengthen the Group’s proposition to global biopharma, healthcare product manufacturers and medical research/regenerative medicine customers, areas in which Select is already proven.

Vertical integration

As a result of the proposed acquisition, the enlarged Group will be able to offer a vertically integrated solution to customers, providing environmentally controlled storage in combination with an enhanced portfolio of laboratory analyses both upstream and downstream to the stability storage offering.

The ability to access stability storage products and laboratory analyses from a single, accredited provider enables customers to streamline the number of service providers and de-risk the process by avoiding unnecessary sample transfers, and minimise logistical administration (compared with using
separate storage and testing service providers in different locations). The Board believes that there is significant demand for such an integrated offering, based on feedback from customers and prospects over the last several years.

The enlarged Group will operate a network of stability storage and laboratory facilities extending across the UK and Ireland and the East and West coasts of the USA. This will enable customers to access a seamless, vertically integrated outsourced solution with consistently-applied laboratory analyses across key geographies.

Expanded customer base and cross-selling

Significant cross-selling opportunities are apparent for the enlarged Group through the offer of an enhanced range of laboratory services to existing Source BioScience customers. Many of Source BioScience’s existing stability storage customers currently procure stability testing and other physical, chemical and microbiological analyses from other laboratory service providers. The proposed
acquisition presents the opportunity for Source BioScience to provide these laboratory services to customers.

Select currently undertakes the laboratory analysis for customer compounds and samples that have been subject to an environmentally controlled storage programme, including stability storage. The enlarged Group will have the potential to offer an outsourced environmentally controlled storage solution for these Select customers in addition to conducting the laboratory analysis.

Select also provides laboratory analyses for applications in batch release and product testing for customers wishing to obtain a license to import, or market, therapeutics in the EU. Its customers do not currently use the existing Source BioScience laboratory and stability storage services offering and this represents a major new opportunity for the enlarged Group. This opportunity extends the Group’s presence into new markets including India, the Far East and China where Select currently has a commercial presence but which represent untapped markets for Source BioScience.

Post-acquisition strategy

Source BioScience and Select bring together complementary skills and expertise, which will enable the enlarged Group to enhance its position as a leading provider of laboratory services. Select will be fully integrated into the Group, enhancing its capability to deliver a broader range of high value testing
services.

Source BioScience will benefit from the enhanced portfolio of laboratory analyses and expertise that Select provides and in addition will be able to access new markets and customers for those services.

At the same time, Select will gain access to existing clients of the Group with substantial volumes of therapeutic and other compounds currently stored under environmentally controlled conditions at Source BioScience’s sites, which will require analytical testing, including batch release testing.

The senior management of Select will stay with the enlarged Group and, in the Board’s view, will contribute considerably to the depth and experience of the Group’s team. This will enable Source BioScience to address the opportunity presented by new customers in new markets and to access new geographies.

Select also has an outstanding reputation for quality which is entirely consistent with the environment and ethos at Source BioScience.

Satisfaction of deferred consideration

Deferred consideration of up to £0.6m is payable two years from completion, of which £0.1 million is payable subject to the performance of the Source BioScience share price. It is intended that the deferred consideration will be met from the future cash resources of the Company.

Financial effects of the proposed acquisition

The circular to be posted to shareholders in connection with the acquisition will contain details of the financial effects of the transaction on the Company, including the funding arrangements. The terms of the new debt facility are materially similar to those entered into in 2013. For illustrative purposes only
the circular contains an unaudited pro forma statement of net assets of the enlarged Group, assuming completion of the acquisition had occurred as at 31 December 2014, showing unaudited pro forma net assets of the enlarged Group of £30.2 million, including net debt of £7.2 million.

Outlook

There is growing demand from the biopharma industry to simplify and shorten the product development to product approval process.

Access to individual suppliers that can deliver a vertically integrated laboratory services solution, addressing multiple elements of the product development pipeline is key to this accelerated pathway and key to de-risking the supply chain.

The enlarged Group will be able to offer an integrated solution to customers, providing environmentally controlled storage in combination with an enhanced portfolio of both upstream and downstream laboratory analyses.

Laboratory analytical testing of product currently stored within the Source BioScience environmentally controlled stability storage suites will fall under the existing capability of Select and further enhance revenue from these activities.

In addition, the Board believes that the enlarged Group will retain the flexibility to realise its additional organic growth objectives and targeted investment opportunities following the proposed acquisition and that Source BioScience will have greater access to funding and other resources required to
pursue its strategy.

Completion

Completion of the proposed acquisition will take place on admission of the new ordinary shares to be issued in connection with the Placing and is conditional on the new debt facility becoming unconditional and the satisfaction of certain other terms and conditions as detailed more fully in Part V of the circular being issued shortly. If any such conditions are not satisfied on or before 31 August 2015 or, if applicable, waived, the acquisition will not proceed.

The Placing is not subject to shareholder approval and is being made under existing authorities to allot the new shares on a non pre-emptive basis. In the event that the acquisition is not approved by shareholders, the Placing will not complete and the Company will not have use of the net proceeds of the Placing.

General Meeting

The acquisition constitutes a Class 1 transaction for Source BioScience under the Listing Rules and therefore requires and is conditional, inter alia, upon the approval of shareholders. Accordingly, a General Meeting will be convened for this purpose and will be held at 1 Orchard Place, Nottingham Business Park, Nottingham NG8 6PX on 14 August 2015 at 10.00am.

The notice of General Meeting will be set out in the circular, which will be posted to shareholders shortly.

Expected timetable of principal events

Each of the times and dates in the table below is indicative only and may be subject to change.

Announcement of the acquisition and the Placing 27 July 2015
General Meeting 14 August 2015
Expected date of admission and commencement of dealings in the new ordinary shares on the London Stock Exchange 17 August 2015
Expected date of completion of the proposed acquisition 17 August 2015

The times and dates set out in the expected timetable of principal events above may be adjusted by Source BioScience, in consultation with N+1 Singer, in which event details of the new times and dates will be notified to the UK Listing Authority and the London Stock Exchange and will be announced via a Regulatory Information Service.

Information on the Placing

The new ordinary shares represent approximately 10% of the Company’s existing issued share capital and will represent approximately 9.1% of the Company’s enlarged issued share capital following the placing. The new ordinary shares will be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares. The new ordinary shares may be held in certificated or
uncertificated form.

The Placing was heavily oversubscribed but capped at approximately £4.4 million in gross proceeds being the maximum amount within the Company’s existing authority to allot new shares on a non pre-emptive basis and without triggering the need for a full prospectus.

Application will be made to the UK Listing Authority for the new ordinary shares to be admitted to the premium listing segment of the Official List and to the London Stock Exchange for the new ordinary shares to be admitted to trading on the London Stock Exchange’s main market for listed securities. It is expected that admission will become effective and that dealings in the new ordinary shares will commence on the London Stock Exchange at 8.00am on 17 August 2015.

buywell3
29/7/2015
07:23
A few thoughts

Source Bioscience had a presence in Biocity prior to this latest acquisition

From the Source Bioscience March 2015 results : 'Operational highlights

• Overnight Service™ for DNA sequencing launched from new laboratories in Los Angeles, BioCity Scotland and Tramore, Ireland


Presumably SBS had its eye on Select Pharma very soon after moving into Biocity if not before.

The acquisition of Vindon Healthcare was questioned by many.

Many investors sold up as they did not see the sense in acquiring a business that manufactured cold storage rooms.

Vindon was located in Rochdale, a new SBS production facility involving Inverclyde products has now been recently located nearby in the same Kingsway business park which allows for future product expansion



The latest Select Pharma acquisition also requires cold storage provision , not surprisingly one would imagine that Vindon units(now SBS owned) will be used in the future and most likely Select Pharma were already leasing some.


It does not take much out of the box thinking to expect SBS to replicate this model in the USA in a year or two.

The integration and replication of Select Pharma services at existing Source Bioscience USA facilities will surely come at some point soon, which will then enable greater market penetration particularly within the states concerned and the neighbouring states.

SBS has now made many acquisitions, this will be the sixth

Vindon was acquired by obtaining institutional cash at 9.5p , which was circa 23% discount on the circa 12.5p share price that SBS was trading at the time.

Select Pharma , which is a private unlisted company , has been acquired using institutional cash at raised at a share price of 14p which was the share price at the time of the announcement


Why is this ?


Private investors have all but sold out now

Over 90% of shares rested in the hands of existing institutional investors and SBS management BEFORE this acquisition

After the acquisition this figure will rise to over 95%

In short , there are hardly any shares left for PI's to trade.


The next acquisition which I expect will come within 18 months to two years , will be similar to this one with just one difference

I expect the cash raised next time will be at a premium to the SP


why ?


SBS turnover and profits for this year are already in the bag as there will be a whole years trading of Vindon products included PLUS there will be some numbers to add from Select Pharma , I now expect over £31.5m turnover ( just over a 20% 2014 rise )and this time over £3m profit, I don't expect too much in the way of charges/costs for the Select Pharma acquisition.

Also has anyone noticed that the number of distributors selling SBS Life Sciences products and services has increased to 18 from a recent 13 some 6 months ago ?

So a 2014 disappointing flat Life Sciences number should start heading north once more, plus Atlanta and the USA should start contributing.

2016 turnover and profits look set rise as there will be a whole year of Select Pharma turnover and profits to be added together with increased cross selling opportunities gained by SBS access to Select Pharma clients and vice versa


plus

there are no shares left so any new institution wanting a meaningful stake will have to pay for it.

SBS management, though I give them a hard time of it sometimes, are proving to be able to deliver the goods.

Their acquisition choices are coming good, have been bought at decent prices , the way that they are gelling together and each new one is helping the rest shows the plan is working.

Controlled growth by acquisition is the name of the game

SBS Market Cap is now over £50m , this might attract some new Institutions that have minimum market cap limits set for investment purposes.

Within 4 years I expect to see Turnover of £50m which will help to do the same

In short , SBS is starting to look like it might be another ABC


dyor

buywell3
29/7/2015
06:00
Select Bio Laboratories moves into BioCity Scotland

9 October 2012


Lanarkshire-based biosciences incubator, BioCity Scotland, has signed a deal with the Select Pharma Group to move its contract testing laboratory services onto the site this month.

Select Bio Laboratories is acquiring 2500sq.ft of bespoke office and laboratory space to provide GMP (Good Manufacturing Practice) pharmaceutical microbiology and biochemical analysis to global pharmaceutical clients. This will help the Group meet its strategy of providing a one-stop shop for pharmaceutical testing.

Named as Scotland’s Best New Life Science Company in the Scottish Enterprise awards this year, Select Pharma is anticipated to grow its Biolab at Newhouse from three to ten staff over the next three years.

Providing highly-specialised testing services to major pharmaceutical companies has become a major source of revenue as the global industry contracts out. Select Biolabs can expect to win further contracts from manufacturers based in North America and Asia whose drug development must comply with EU regulations. BioCity has overseen the re-fitting of the laboratories; a sterile testing area and bespoke microbiological and biological laboratories, fitted out to meet Select Bio Laboratories specifications.

Steve Hastwell, Technical Director for Select Bio Laboratories is overseeing the move into the new facility: “BioCity Scotland is an ideal base for us. The quality of the laboratory facilities is world-class so the additional re-fitting gives us exactly what we need. We also want to be associated with BioCity’s success in establishing itself as a major provider of support to Scotland’s life science businesses. I have no doubt that being based here will bring opportunities to promote our services to the wider life science community in Scotland.”

Select Pharma Laboratories was established in 2010 by David Clapperton and Joanne Parkin, industry professionals with extensive experience in pharmaceutical manufacturing and contract testing services. The laboratory in Stirling achieved MHRA approval in October 2010. Since then the company has grown rapidly with an absolute focus on customer service throughout the organisation. This has produced consistent delivery of high standards of service.

In November 2011 a second facility was commissioned in Stirling, housing a specialist Stability Storage suite, and the latest addition to the Group activities is Select Bio Laboratories at Biocity. The company has received assistance from Scottish Enterprise and Scottish Development International.

The arrival of Select Bio Laboratories brings to eleven the companies now using the BioCity Scotland facilities and support. Launched in January this year, the company has worked hard to bring the 130,000 sq ft site and highly specialised laboratory equipment into use again, and has also brought several corporate partners alongside to provide professional services for tenants. Select Bio Laboratories will have access to legal, accounting and IP experts who now deliver regular workshops on site.

Fraser Black, MD of BioCity Scotland says: “We are delighted to count Scotland’s Best New Life Science company amongst our growing group of tenants. The calibre of management and scientific expertise shown by the team is testament to the strength of the Scottish life sciences sector, and BioCity is just the location for such as aspirational organisation. We look forward to helping them with their growth plans.”

buywell3
28/7/2015
19:15
Excellent call
peterz
28/7/2015
17:21
buywell2 - 10 Mar 2015 - 08:05:16 - 3037 of 3114

Chartwise the 100 day average looks in a good place

Any reasonable news now and 16p could soon follow on

dyor

buywell3
28/7/2015
16:26
doing better than holding.. up again today...new high ?
bigman
28/7/2015
14:45
Well the price is still holding so, I guess, the insti's and City are ok with it, the deal. As you suggest they will have had a presentation and know much better about what is a good deal and what the future can hold for us. Onwards and upwards.
peterz
28/7/2015
09:53
(mmm... my first thoughts concur with you (hence post 3118) however there are a few pointers .... first these guys are no mugs ( our board) second the shares placed at no discount and with institutions that would have had a presentation no doubt. third and most significant is the quote about select " it has continued on same track in past year" well if that is correct and it must be as they said it then Revenues are now double at £4m pretax profits are now at £738k ( up 28%) and cash at £1.2m so that being the case it is now better than buywell at 2 time turnover equates to £8m and 10 times profit £7.38m. which is spot on. and if we can grow it at same rate from this then it is a very very cheap buy.....
my faith is restored

bigman
28/7/2015
07:56
So how do we aire our views to CEO. And as share holders do we have any right to an explanation... Of course we do. It is our money being spent. Is it being spent wisely? We need to see the boards actions reflected in the share price.

Buywell. I am in no way questioning your suggestion that we the company have paid too much, much too much it seems. But I would like to know what we can do to make our point to the board.

peterz
28/7/2015
06:51
average of 2 times turnover and 10 times profits is the norm now
buywell3
28/7/2015
06:50
does look like a high price to me
bigman
28/7/2015
06:39
Select Pharma snapped up in £7.3m deal
Tuesday 28 July 2015

Select Pharma, the Dunblane-based laboratory testing company, has been acquired for up to £7.3million by main market-listed Source Bioscience.

It represents a £5million windfall for majority shareholder David Clapperton whose wife Morag is also on the board, and a £1.8m payout for Gerald Higgins, chairman since 2013.

Privately-owned Select, founded in November 2009, provides stability storage and testing laboratory services, and three years ago it moved its testing facilities to the BioCity Scotland business incubator site at Newhouse in Lanarkshire.

The company doubled revenues to £2m and net assets to £1.3m over the two years to March 2014, and lifted pre-tax profit from £453,000 to £578,000. Its cash flow from operations more than doubled to £643,000 between 2013 and 2014, and it is debt-free.

Source, based in Nottingham and with a market capitalisation of £46million, said the Scottish firm had continued on the same track in the past year. “Select has grown consistently in recent years to become a leading European provider of stability testing with attractive, sustained operating margins and a robust, growing sales pipeline.”


Select's customers include contract drug manufacturers, European generics distributors and UK and EU importers of medicinal products, amid growing demand for accredited testing to support drug import licence applications, and it is located close to Source Bioscience's Scottish base.

Source has raised £4.4m from investors in a placing, and £3.5m in new debt, to finance the £7.3m in cash, of which £600,000 is deferred for two years.

buywell3
27/7/2015
16:03
Well I guess everyone has the same figures and our Co decided to pay almost double its value on your figures, Buywell. Well its held 15p.
peterz
27/7/2015
07:14
£7.3m looks too much I am afraid unless the company has won some contract of which we are not aware or SBS are able to win a sizeable contract with the acquisition of Select Pharma

From the numbers below I would have thought anything above £4m was paying over the odds

buywell3
27/7/2015
06:19
buywell2 - 10 Mar 2015 - 08:05:16 - 3037 of 3114

Chartwise the 100 day average looks in a good place

Any reasonable news now and 16p could soon follow on

dyor

buywell3
20/7/2015
08:10
Or News announced today by Government that cancer tests/testing to increase by 80%.
bartdude
16/7/2015
10:42
They will know results Jan to June 30th - ?

We will know when Interims out / Sept?..

bartdude
16/7/2015
09:05
Some very one sided trading on here this morning! Good news due?
diamond1
09/7/2015
06:29
good to see recovery of share price and the graph looks excellent , reflecting a growing company with lots of growth in the years ahead and profits, the latter is not the norm in this sector, added a few more, really like what this company does both in its business and financial performance, quality business.
bigman
Chat Pages: 136  135  134  133  132  131  130  129  128  127  126  125  Older

Your Recent History

Delayed Upgrade Clock